The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor response and growth rate of nivolumab treatment in advanced gastric cancer: Real-world data from a large observational/translational study, JACCRO GC-08 (deliver trial).
 
Ryohei Kawabata
No Relationships to Disclose
 
Yasuhiro Sakamoto
No Relationships to Disclose
 
Eisuke Inoue
Consulting or Advisory Role - Pfizer
Speakers' Bureau - Bristol-Myers Squibb Japan
 
Atsushi Ishiguro
No Relationships to Disclose
 
Yusuke Akamaru
No Relationships to Disclose
 
Yosuke Kito
No Relationships to Disclose
 
Masazumi Takahashi
No Relationships to Disclose
 
Jin Matsuyama
No Relationships to Disclose
 
Hiroshi Yabusaki
No Relationships to Disclose
 
Akitaka Makiyama
Speakers' Bureau - Chugai Pharma; Lilly; Takeda
 
Takahisa Suzuki
No Relationships to Disclose
 
Masahiro Tsuda
No Relationships to Disclose
 
Hisateru Yasui
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Taiho Pharmaceutical; TERUMO; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Ryo Matoba
Leadership - DNA Chip Research
Stock and Other Ownership Interests - DNA Chip Research
 
Kei Muro
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Mediscience Planning (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Parexel International (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Solasia Pharma (Inst); Sumitomo Dainippon (Inst)
 
Takako Eguchi Nakajima
Honoraria - Bayer; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Dainippon Sumitomo Pharma; Kyowa Hakko Kirin; Lilly Japan; MERCK SERONO; MSD; Nippon Kayaku; Ono Pharmaceutical; Sanofi; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda; Teijin Pharma
Research Funding - A2 Healthcare; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Lilly Japan; Merck Serono; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; Sanofi; Solasia Pharma (Inst); Taiho Pharmaceutical; Takeda
 
Wataru Ichikawa
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck Serono
Research Funding - Chugai Pharma (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masashi Fujii
Travel, Accommodations, Expenses - Japan Clinical Cancer Research Organization; Taiho Pharmaceutical
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck; Nippon Kayaku; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Merck Serono (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)